Doctor Balazs Muk

Doctor Balazs Muk

Gottsegen National Cardiovascular Center, Budapest (Hungary)

Member of:

MD, PhD, FESC, Specialist of Internal Medicine and Cardiology, Heart Failure specialist certified by ESC HFA, endorsed by BSH and BCS, Secretary of Working Group on Heart Failure, Hungarian Society of Cardiology, Head of the Heart Failure Unit, Gottsegen National Cardiovascular Center, Department of Adult Cardiology

Presentations Articles

The impact of comorbidities on therapy-optimization and their prognostics role among hospitalized patients with heart failure with reduced ejection fraction

Event: ESC Congress 2024

Topic: Comorbidities

Session: Heart and kidney in heart failure: no end to the dangerous liaison

Access

Rapid up-titration of the guideline directed medical therapy after a heart failure hospitalization in the daily clinical practice: a case series

Event: ESC Congress 2024

Topic: Clinical

Session: Chronic heart failure

Access

Impact of the guideline-directed medical therapy on the eligibility of patients for mitral valve transcatheter edge-to-edge repair in HFrEF

Event: Heart Failure 2024

Topic: Pharmacotherapy

Session: Chronic heart failure - treatment 13

Access

Assessment of the impact of multidisciplinary heart failure outpatient care on the prognosis in HFrEF

Event: Heart Failure 2023

Topic: Treatment

Session: Chronic heart failure - treatment 1

Access

The effect of kidney dysfunction on introducing guideline-derived medical therapy and on mortality among hospitalized patients with heart failure with reduced ejection fraction

Event: ESC Congress 2022

Topic: Pharmacotherapy

Session: Chronic heart failure - The kidney and heart failure

Access

The prevalence of RAASi uptitration limiting hyperkalemia and the suitability of potassium binders among patients suffering from heart failure with reduced ejection fraction

Event: ESC Congress 2020

Topic: Pharmacotherapy

Session: Chronic Heart Failure ePosters

Access

The impact of highest doses of ACEi/ARB therapy on mortality of patients suffering from heart failure with reduced ejection fraction: a long-term follow-up, propensity-matched cohort study

Event: ESC Congress 2019

Topic: Pharmacotherapy

Session: Treatment of heart failure

Access

Have we found the Holy Grail in Heart failure with reduced ejection fraction? - First experiences with sacubitril/valsartan among heart transplant candidates

Event: Heart Failure 2019

Topic: Pharmacotherapy

Session: Clinical Cases

Access

The impact of serum concentration guided digoxin therapy on mortality: a long-term follow-up, propensity-matched cohort study

Event: ESC Congress 2018

Topic: Pharmacotherapy

Session: Strategies to optimize established heart failure therapies

Access

The effect of treatment optimization on the prevalence of sleep disordered breathing and on its phenotype among patients hospitalized with acute decompensated heart failure

Event: Heart Failure 2018

Topic: Comorbidities

Session: Chronic Heart Failure - Clinical

Access

ESC 365 is supported by

Explore sponsored resources

Doctor Balazs Muk

Biography

Contributor content

The impact of comorbidities on therapy-optimization and their prognostics role among hospitalized patients with heart failure with reduced ejection fraction

Rapid up-titration of the guideline directed medical therapy after a heart failure hospitalization in the daily clinical practice: a case series

Impact of the guideline-directed medical therapy on the eligibility of patients for mitral valve transcatheter edge-to-edge repair in HFrEF

Assessment of the impact of multidisciplinary heart failure outpatient care on the prognosis in HFrEF

The effect of kidney dysfunction on introducing guideline-derived medical therapy and on mortality among hospitalized patients with heart failure with reduced ejection fraction

The prevalence of RAASi uptitration limiting hyperkalemia and the suitability of potassium binders among patients suffering from heart failure with reduced ejection fraction

The impact of highest doses of ACEi/ARB therapy on mortality of patients suffering from heart failure with reduced ejection fraction: a long-term follow-up, propensity-matched cohort study

Have we found the Holy Grail in Heart failure with reduced ejection fraction? - First experiences with sacubitril/valsartan among heart transplant candidates

The impact of serum concentration guided digoxin therapy on mortality: a long-term follow-up, propensity-matched cohort study

The effect of treatment optimization on the prevalence of sleep disordered breathing and on its phenotype among patients hospitalized with acute decompensated heart failure

ESC 365 is supported by

Doctor Balazs Muk Follow

Biography

Contributor content

The impact of comorbidities on therapy-optimization and their prognostics role among hospitalized patients with heart failure with reduced ejection fraction

Rapid up-titration of the guideline directed medical therapy after a heart failure hospitalization in the daily clinical practice: a case series

Impact of the guideline-directed medical therapy on the eligibility of patients for mitral valve transcatheter edge-to-edge repair in HFrEF

Assessment of the impact of multidisciplinary heart failure outpatient care on the prognosis in HFrEF

The effect of kidney dysfunction on introducing guideline-derived medical therapy and on mortality among hospitalized patients with heart failure with reduced ejection fraction

The prevalence of RAASi uptitration limiting hyperkalemia and the suitability of potassium binders among patients suffering from heart failure with reduced ejection fraction

The impact of highest doses of ACEi/ARB therapy on mortality of patients suffering from heart failure with reduced ejection fraction: a long-term follow-up, propensity-matched cohort study

Have we found the Holy Grail in Heart failure with reduced ejection fraction? - First experiences with sacubitril/valsartan among heart transplant candidates

The impact of serum concentration guided digoxin therapy on mortality: a long-term follow-up, propensity-matched cohort study

The effect of treatment optimization on the prevalence of sleep disordered breathing and on its phenotype among patients hospitalized with acute decompensated heart failure

ESC 365 is supported by

Doctor Balazs Muk